AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

As for Chia Tai Feng Hai, the company is owned by parent company Sino Biopharmaceutical, a large China pharma based in Hong ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.  | Full-year sales for Roche’s diagnostics division were up by just 2% as ...

Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared to be the final RIPK1 inhibitor from the deal. | Sanofi is ...

Like many life sciences outfits undergoing a restructuring, Charles River Laboratories is balancing layoffs and a business ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

The oncology biotech plans to offer 17,648,000 shares at $17 a pop, according to a Jan. 28 filing with the Securities and Exchange Commission. The maximum price outlined by Eikon is $18 per share, ...